Kmc Speciality Hospitals India Ltd vs Lotus Eye Hospital Institute Ltd Stock Comparison
Kmc Speciality Hospitals India Ltd vs Lotus Eye Hospital Institute Ltd Stock Comparison
Last Updated on: Oct 24, 2026
Key Highlights
The Latest Trading Price of KMC Speciality Hospitals (India) Ltd is ₹ 144.2 as of 23 Oct 15:30
. The P/E Ratio of KMC Speciality Hospitals (India) Ltd changed from 28 on March 2021 to 27.4 on March 2026 . This represents a CAGR of -0.36% over 6 yearsThe P/E Ratio of Lotus Eye Hospital & Institute Ltd changed from 55.9 on March 2021 to 2533 on March 2026 . This represents a CAGR of 88.83% over 6 years The Market Cap of KMC Speciality Hospitals (India) Ltd changed from ₹ 355.56 crore on March 2021 to ₹ 1284 crore on March 2026 . This represents a CAGR of 23.87% over 6 yearsThe Market Cap of Lotus Eye Hospital & Institute Ltd changed from ₹ 87.14 crore on March 2021 to ₹ 210.77 crore on March 2026 . This represents a CAGR of 15.86% over 6 years The revenue of KMC Speciality Hospitals (India) Ltd for the Jun '26 is ₹ 93.58 crore as compare to the Mar '26 revenue of ₹ 84.16 crore. This represent the growth of 11.19% The revenue of Lotus Eye Hospital & Institute Ltd for the Jun '26 is ₹ 17.27 crore as compare to the Mar '26 revenue of ₹ 14.09 crore. This represent the growth of 22.57% The ebitda of KMC Speciality Hospitals (India) Ltd for the Jun '26 is ₹ 30.29 crore as compare to the Mar '26 ebitda of ₹ 27.78 crore. This represent the growth of 9.04% The ebitda of Lotus Eye Hospital & Institute Ltd for the Jun '26 is ₹ 3.15 crore as compare to the Mar '26 ebitda of ₹ 0.95 crore. This represent the growth of 231.58% The net profit of KMC Speciality Hospitals (India) Ltd changed from ₹ 5.51 crore to ₹ 16.57 crore over 9 quarters. This represents a CAGR of 63.12%
The net profit of Lotus Eye Hospital & Institute Ltd changed from ₹ 0.62 crore to ₹ 0.61 crore over 9 quarters. This represents a CAGR of -0.72%
The Dividend Payout of KMC Speciality Hospitals (India) Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Lotus Eye Hospital & Institute Ltd changed from 66.24 % on March 2021 to 0 % on March 2026 . This represents a CAGR of -100.00% over 6 years .
About KMC Speciality Hospitals (India) Ltd
KMC Speciality Hospitals (India) Limited was originally incorporated as 'Advanced Medical Care Private Limited' on December 31, 1982 and was converted into a Public Limited Company on July 15, 1988.
The name of the Company was changed to 'Seahorse Hospitals Limited' on March 21, 1995 and to its current name 'KMC Speciality Hospitals (India) Limited' with effect from October 24, 2008.
The Company is a part of the KMC Group of Hospitals based at Tiruchirappalli.
The Company is a super speciality hospital based in Trichy, belonging to the Kauvery Hospitals Group.
The Company is primarily engaged in the business of rendering medical and healthcare services.
It provide quality healthcare to patients in key specialty areas such as Neurosurgery, Cardiovascular & thoracic surgery, Orthopedics, Plastic and Reconstructive Surgery, Gynecology, Neonatology and Nephrology (including renal transplants).
About Lotus Eye Hospital & Institute Ltd
Lotus Eye Hospital & Institute Limited, a trust hospital, was originally incorporated as 'Kalaivani Health Centre Pvt.
Limited' on 14 March, 1997.
The name of the Company was changed to 'Lotus Eye Care Hospital Pvt.
Limited' on 23 January, 2006 and later on, the Company was converted into a Public Limited Company on October 16, 2007 and subsequently, the name was changed to Lotus Eye Hospital & Institute Limited on April 12, 2013.
Founded in 1990 by renowned ophthalmic surgeon late Dr. S.K. Sundaramoorthy, the Company operates 9 Eye Care centers in Tamil Nadu and Kerala: 7 Centres in Tamil Nadu: Coimbatore (Peelamedu, RS puramand Saravanampatti), Salem , Tirupur Mettupalayam and Karur. 2 Centresin Kerala: Kochi and Mulanthuruthy.
Lotus Eye Care Hospital is the state of art eye care hospital group functioning in South India with specialization in super-specialty service related to eye care.
FAQs for the comparison of KMC Speciality Hospitals (India) Ltd and Lotus Eye Hospital & Institute Ltd
Which company has a larger market capitalization, KMC Speciality Hospitals (India) Ltd or Lotus Eye Hospital & Institute Ltd?
Market cap of KMC Speciality Hospitals (India) Ltd is 2,351 Cr while Market cap of Lotus Eye Hospital & Institute Ltd is 234 Cr
What are the key factors driving the stock performance of KMC Speciality Hospitals (India) Ltd and Lotus Eye Hospital & Institute Ltd?
The stock performance of KMC Speciality Hospitals (India) Ltd and Lotus Eye Hospital & Institute Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for KMC Speciality Hospitals (India) Ltd and Lotus Eye Hospital & Institute Ltd?
As of October 24, 2026, the KMC Speciality Hospitals (India) Ltd stock price is INR ₹144.2. On the other hand, Lotus Eye Hospital & Institute Ltd stock price is INR ₹112.75.
How do dividend payouts of KMC Speciality Hospitals (India) Ltd and Lotus Eye Hospital & Institute Ltd compare?
To compare the dividend payouts of KMC Speciality Hospitals (India) Ltd and Lotus Eye Hospital & Institute Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.